Gene therapy as a vaccine for HIV-1

Author(s): Berkhout B, Sanders RW

Abstract

Introduction: An effective vaccine that can protect people against infection of the human immunodeficiency virus type 1 (HIV-1) remains elusive. HIV-1 vaccine research has encountered several false starts and a few causes for hope over the last 28 years, but no real success stories. Thus, it is time to think out of the box and design and test unorthodox vaccination strategies.

Areas covered: Recent studies in mice and monkeys have revealed the potential of a gene therapy that provides vaccine-like protection against HIV-1 infection by producing a potent vector-encoded antibody that neutralizes the invading viruses. This novel strategy is called Vectored Immuno Prophylaxis or VIP, and it circumvents the sometimes difficult phases of regular vaccination protocols, that is, antigen design and induction of protective immune responses.

Expert opinion: VIP is a prolonged form of passive immunization by means of a gene therapy. We will discuss the ins and outs of VIP and the therapeutic possibilities and challenges.

Similar Articles

Trial, error and breakthrough: A review of HIV vaccine development

Author(s): Barry SM, Mena Lora AJ, Novak RM

Cell responses to HIV-1 infection and vaccination: pathways to preventing infection

Author(s): Haynes BF, Moody MA, Liao HX, Verkoczy L, Tomaras GD

The antigenic structure of the HIV gp120 envelope glycoprotein

Author(s): Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, et al.

Crystal structure of a soluble cleaved HIV-1 envelope trimer

Author(s): Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, et al.

Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer

Author(s): Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, et al.

Antibody gene transfer for HIV immunoprophylaxis

Author(s): Balazs AB, West AP

Rapamycin-regulated control of antiangiogenic tumor therapy following raav-mediated gene transfer

Author(s): Nguyen M, Huan-Tu G, Gonzalez-Edick M, Rivera VM, Clackson T, et al.

Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation

Author(s): Hütter G, Nowak D, Mossner M, Ganepola S, Müßig A, et al.

Novel targets for antiretroviral therapy

Author(s): Dau B, Holodniy M.

Study record detail USA

Author(s): US National library of Medicine

Study record detail USA

Author(s): US National library of Medicine

Study record detail USA

Author(s): US National library of Medicine

Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env

Author(s): Scharf L, Wang H, Gao H, Chen S, McDowall AW, et al.